(“Ananda” or the “Company”)
Total Voting Rights
In accordance with the
This figure of 418,055,554 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the
The directors of the Company accept responsibility for the contents of this announcement.
Ananda Developments plc+44 (0)20 7520 9266 CEO firstname.lastname@example.org Melissa SturgessInvestor Relations Jeremy Sturgess-Smith Peterhouse Capital Limited+44 (0)20 7469 0930 Corporate Finance Fungai Ndoro Mark AnwylCorporate Broker Lucy Williams Duncan Vasey Stanford Capital Partners Limited+44 (0)20 3815 8880 Corporate Broker John Howes Patrick Claridge Celicourt CommunicationsMark Antelme Ollie Mills
Notes to editors
Ananda Developments invests in the developing market for medical or therapeutic Cannabis derivatives, or related products, including but not limited to nutraceuticals, dietary supplements and cosmetic products which contain Cannabis or hemp derived cannabinoids. The Directors believe that this market is growing due to an increasing number of states in the
A copy of the Company’s Admission Document is available at www.anandadevelopments.com/wp-content/uploads/2019/03/ANANDA-DEVELOPMENTS-Admission-Document-29.06.2018-FINAL-clean.pdf
Ananda’s investment strategy is to invest in companies, projects or products that are progressing medical or therapeutic Cannabis research and development, or seeking to produce or cultivate Cannabis in any jurisdiction in which it is legal to do so, or are developing or have already developed, products that contain Cannabis derived cannabinoids and require funding to progress work plans or commercialise products.